Institution
Capital Medical University
Education•Beijing, China•
About: Capital Medical University is a education organization based out in Beijing, China. It is known for research contribution in the topics: Population & Medicine. The organization has 56150 authors who have published 47290 publications receiving 811249 citations.
Topics: Population, Medicine, Stroke, Cancer, Randomized controlled trial
Papers published on a yearly basis
Papers
More filters
••
Peking Union Medical College1, Sun Yat-sen University2, Academy of Military Medical Sciences3, Tongji University4, Capital Medical University5, Third Military Medical University6, Second Military Medical University7, Central South University8, Fourth Military Medical University9, Guangdong General Hospital10, Zhejiang University11, Southern Medical University12, Fudan University13, Shanghai Jiao Tong University14, Beta15, Beijing Chao-Yang Hospital16, Peking University17
TL;DR: Icotinib was non-inferior to gefitinib in terms of progression-free survival and could be a new treatment option for pretreated patients with advanced non-small-cell lung cancer.
Abstract: Summary Background Icotinib, an oral EGFR tyrosine kinase inhibitor, had shown antitumour activity and favourable toxicity in early-phase clinical trials. We aimed to investigate whether icotinib is non-inferior to gefitinib in patients with non-small-cell lung cancer. Methods In this randomised, double-blind, phase 3 non-inferiority trial we enrolled patients with advanced non-small-cell lung cancer from 27 sites in China. Eligible patients were those aged 18–75 years who had not responded to one or more platinum-based chemotherapy regimen. Patients were randomly assigned (1:1), using minimisation methods, to receive icotinib (125 mg, three times per day) or gefitinib (250 mg, once per day) until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival, analysed in the full analysis set. We analysed EGFR status if tissue samples were available. All investigators, clinicians, and participants were masked to patient distribution. The non-inferiority margin was 1·14; non-inferiority would be established if the upper limit of the 95% CI for the hazard ratio (HR) of gefitinib versus icotinib was less than this margin. This study is registered with ClinicalTrials.gov, number NCT01040780, and the Chinese Clinical Trial Registry, number ChiCTR-TRC-09000506. Findings 400 eligible patients were enrolled between Feb 26, 2009, and Nov 13, 2009; one patient was enrolled by mistake and removed from the study, 200 were assigned to icotinib and 199 to gefitinib. 395 patients were included in the full analysis set (icotinib, n=199; gefitinib, n=196). Icotinib was non-inferior to gefitinib in terms of progression-free survival (HR 0·84, 95% CI 0·67–1·05; median progression-free survival 4·6 months [95% CI 3·5–6·3] vs 3·4 months [2·3–3·8]; p=0·13). The most common adverse events were rash (81 [41%] of 200 patients in the icotinib group vs 98 [49%] of 199 patients in the gefitinib group) and diarrhoea (43 [22%] vs 58 [29%]). Patients given icotinib had less drug-related adverse events than did those given gefitinib (121 [61%] vs 140 [70%]; p=0·046), especially drug-related diarrhoea (37 [19%] vs 55 [28%]; p=0·033). Interpretation Icotinib could be a new treatment option for pretreated patients with advanced non-small-cell lung cancer. Funding Zhejiang Beta Pharma (China), the Chinese National Key Special Program for Innovative Drugs, the 863 Project, and Zhejiang Provincial Key Special Program.
360 citations
••
TL;DR: In December 2019, a cluster of acute respiratory illness occurred in Wuhan, Hubei Province, China and this disease is now officially known as 2019 novel coronavirus disease (COVID-19) from World Health Organization.
Abstract: In December 2019, a cluster of acute respiratory illness occurred in Wuhan, Hubei Province, China This disease is now officially known as 2019 novel coronavirus disease (COVID-19) from WHO, novel coronavirus pneumonia This article is protected by copyright All rights reserved
359 citations
••
TL;DR: It is demonstrated that the pattern of functional connectivity of the motor network in the resting state is disrupted in PD, and this change is secondary to dopamine deficiency, and related to the severity of the disease.
358 citations
••
TL;DR: The methods used for assessing balance in covariates after PSM are outlined, which include standardized mean difference (SMD), which is the most commonly used statistic to examine the balance of covariate distribution between treatment groups.
Abstract: Propensity score matching (PSM) is a popular method in clinical researches to create a balanced covariate distribution between treated and untreated groups. However, the balance diagnostics are often not appropriately conducted and reported in the literature and therefore the validity of the findings from the PSM analysis is not warranted. The special article aims to outline the methods used for assessing balance in covariates after PSM. Standardized mean difference (SMD) is the most commonly used statistic to examine the balance of covariate distribution between treatment groups. Because SMD is independent of the unit of measurement, it allows comparison between variables with different unit of measurement. SMD can be reported with plot. Variance is the second central moment and should also be compared in the matched sample. Finally, a correct specification of the propensity score model (e.g., linearity and additivity) should be re-assessed if there is evidence of imbalance between treated and untreated. R code for the implementation of balance diagnostics is provided and explained.
358 citations
••
Monash University1, University of North Carolina at Chapel Hill2, University of Melbourne3, Walter and Eliza Hall Institute of Medical Research4, Research Institute of Molecular Pathology5, University of Birmingham6, Chinese Academy of Sciences7, University of Adelaide8, University of Minnesota9, Capital Medical University10, Centenary Institute11, Indiana University12, Rush University Medical Center13, Monash University, Clayton campus14
TL;DR: Follicular cytotoxic T cells (TFC cells) as discussed by the authors were identified as a specialized group of T cells that expressed the chemokine receptor CXCR5, selectively entered B cell follicles and eradicated infected TFH cells and B cells.
Abstract: During unresolved infections, some viruses escape immunological control and establish a persistant reservoir in certain cell types, such as human immunodeficiency virus (HIV), which persists in follicular helper T cells (TFH cells), and Epstein-Barr virus (EBV), which persists in B cells. Here we identified a specialized group of cytotoxic T cells (TC cells) that expressed the chemokine receptor CXCR5, selectively entered B cell follicles and eradicated infected TFH cells and B cells. The differentiation of these cells, which we have called 'follicular cytotoxic T cells' (TFC cells), required the transcription factors Bcl6, E2A and TCF-1 but was inhibited by the transcriptional regulators Blimp1, Id2 and Id3. Blimp1 and E2A directly regulated Cxcr5 expression and, together with Bcl6 and TCF-1, formed a transcriptional circuit that guided TFC cell development. The identification of TFC cells has far-reaching implications for the development of strategies to control infections that target B cells and TFH cells and to treat B cell-derived malignancies.
351 citations
Authors
Showing all 56323 results
Name | H-index | Papers | Citations |
---|---|---|---|
Yang Yang | 171 | 2644 | 153049 |
Hua Zhang | 163 | 1503 | 116769 |
Matthias Egger | 152 | 901 | 184176 |
Jost B. Jonas | 132 | 1158 | 166510 |
Shuai Liu | 129 | 1095 | 80823 |
Yang Liu | 129 | 2506 | 122380 |
Chao Zhang | 127 | 3119 | 84711 |
Michael Wang | 117 | 1428 | 56282 |
Wei Lu | 111 | 1973 | 61911 |
Yan Zhang | 107 | 2410 | 57758 |
Claus Bachert | 106 | 842 | 49557 |
Nan Lin | 105 | 687 | 54545 |
Banglin Chen | 105 | 393 | 55287 |
Ming Li | 103 | 1669 | 62672 |
George F. Gao | 102 | 793 | 82219 |